| Avinash Pillutla, | |
|
2810 North Parham Road, Suite 315, Richmond, VA 23294-5051 | |
| (804) 288-8327 | |
| (804) 282-3744 |
| Full Name | Avinash Pillutla |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 9 Years |
| Location | 2810 North Parham Road, Suite 315, Richmond, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659758456 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 0101271653 (Virginia) | Secondary |
| 2085R0204X | Radiology - Vascular & Interventional Radiology | 0101271653 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bon Secours Memorial Regional Medical Center | Mechanicsville, VA | Hospital |
| Bon Secours St Marys Hospital | Richmond, VA | Hospital |
| Bon Secours St Francis Medical Center | Midlothian, VA | Hospital |
| Southside Regional Medical Center | Petersburg, VA | Hospital |
| Bon Secours Mary Immaculate Hospital | Newport news, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aligned Interventional Center | 7911358759 | 4 |
| Commonwealth Radiology Pc | 9830142496 | 39 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Clerity Healthcare, a leading provider of end-to-end IT solutions, today announced that it has been selected by GE Healthcare as the exclusive systems integration technical solutions provider for GE Centricity Practice Solution and Centricity Electronic Medical Records (EMR) customers.
Epilepsy affects about 50 million people worldwide, and while anticonvulsant medications can reduce the frequency of seizures, the drugs are ineffective for as many as one in three patients.
Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.
Bruker Corporation today announces the signing of an agreement to acquire the Scanning Probe Microscopy (SPM) and Optical Industrial Metrology (OIM) instruments business from Veeco Instruments, Inc. for $229 million in cash. The transaction has been approved by the Boards of Directors of both companies and is expected to close during the fourth quarter of 2010, pending regulatory review and subject to customary closing conditions.
› Verified 9 days ago
| Entity Name | Commonwealth Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588613400 PECOS PAC ID: 9830142496 Enrollment ID: O20050224000091 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Clerity Healthcare, a leading provider of end-to-end IT solutions, today announced that it has been selected by GE Healthcare as the exclusive systems integration technical solutions provider for GE Centricity Practice Solution and Centricity Electronic Medical Records (EMR) customers.
Epilepsy affects about 50 million people worldwide, and while anticonvulsant medications can reduce the frequency of seizures, the drugs are ineffective for as many as one in three patients.
Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.
Bruker Corporation today announces the signing of an agreement to acquire the Scanning Probe Microscopy (SPM) and Optical Industrial Metrology (OIM) instruments business from Veeco Instruments, Inc. for $229 million in cash. The transaction has been approved by the Boards of Directors of both companies and is expected to close during the fourth quarter of 2010, pending regulatory review and subject to customary closing conditions.
› Verified 9 days ago
| Entity Name | Aligned Interventional Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881473247 PECOS PAC ID: 7911358759 Enrollment ID: O20240105003126 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Clerity Healthcare, a leading provider of end-to-end IT solutions, today announced that it has been selected by GE Healthcare as the exclusive systems integration technical solutions provider for GE Centricity Practice Solution and Centricity Electronic Medical Records (EMR) customers.
Epilepsy affects about 50 million people worldwide, and while anticonvulsant medications can reduce the frequency of seizures, the drugs are ineffective for as many as one in three patients.
Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.
Bruker Corporation today announces the signing of an agreement to acquire the Scanning Probe Microscopy (SPM) and Optical Industrial Metrology (OIM) instruments business from Veeco Instruments, Inc. for $229 million in cash. The transaction has been approved by the Boards of Directors of both companies and is expected to close during the fourth quarter of 2010, pending regulatory review and subject to customary closing conditions.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Avinash Pillutla, 2810 North Parham Road, Suite 315, Richmond, VA 23294-5051 Ph: (804) 288-8327 | Avinash Pillutla, 2810 North Parham Road, Suite 315, Richmond, VA 23294-5051 Ph: (804) 288-8327 |
News Archive
Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).
Clerity Healthcare, a leading provider of end-to-end IT solutions, today announced that it has been selected by GE Healthcare as the exclusive systems integration technical solutions provider for GE Centricity Practice Solution and Centricity Electronic Medical Records (EMR) customers.
Epilepsy affects about 50 million people worldwide, and while anticonvulsant medications can reduce the frequency of seizures, the drugs are ineffective for as many as one in three patients.
Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.
Bruker Corporation today announces the signing of an agreement to acquire the Scanning Probe Microscopy (SPM) and Optical Industrial Metrology (OIM) instruments business from Veeco Instruments, Inc. for $229 million in cash. The transaction has been approved by the Boards of Directors of both companies and is expected to close during the fourth quarter of 2010, pending regulatory review and subject to customary closing conditions.
› Verified 9 days ago
Dr. Christine H Llewellyn, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1250 E Marshall Street, Radiology, Richmond, VA 23298 Phone: 804-828-8262 Fax: 804-828-6129 | |
Kathryn S. Jones, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1250 E Marshall St, Richmond, VA 23298 Phone: 804-628-3580 Fax: 804-628-3593 | |
Dr. Richard Westwood Fuller, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2602 Buford Rd, Richmond, VA 23235 Phone: 804-272-8806 | |
Michelle S. Kraut, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 7110 Forest Ave, Suite 100, Richmond, VA 23226 Phone: 804-673-4200 Fax: 804-673-6513 | |
Dr. Matthew L Cohen, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2602 Buford Rd, Richmond, VA 23235 Phone: 804-272-8806 | |
Dr. Roger Headly Tutton, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1839 Monument Ave, Richmond, VA 23220 Phone: 804-355-7788 | |
Ryan D Clayton, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1250 E Marshall St, Radiology, Richmond, VA 23298 Phone: 804-628-6831 Fax: 804-628-1132 |